Drug intelligence / Profile preview

JMEY-PR03

Development stage: Preclinical
Lead developer: Jianming Pharmaceutical Group

Overview

JMEY-PR03 is an investigational drug candidate being developed by Jianming Pharmaceutical Group (also known as Wuhan Jianmin Pharmaceutical) for the treatment of epilepsy. It is currently in the preclinical development phase, which encompasses Chemistry, Manufacturing, and Controls (CMC) activities and early pharmacological evaluation. As of the latest pipeline disclosures, the specific molecular target, mechanism of action, and modality (such as small molecule or biologic) have not been publicly identified by the developer.

Beyond the preview

Go deeper on JMEY-PR03.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JMEY-PR03.

Explore the full profile